As­traZeneca, Alex­ion close mas­sive $39B merg­er; blue­bird bio earns EU nod for Lenti-D as big split ap­proach­es

With the fi­nal hur­dle re­cent­ly cleared, As­traZeneca and Alex­ion can fi­nal­ly cel­e­brate their $39 bil­lion merg­er.

The drug­mak­ers closed their ma­jor M&A pact Wednes­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.